HemaCare announces expansion of disease state cells for bioresearch
HemaCare Corporation announced that it has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers. Recent additions to the portfolio include serum from rare diseases such as Granulomatosis with Polyangiitis, and Mixed Connective Tissue Disease, Dermatomyositis and Polymyositis, as well as plasma or serum from infectious diseases including HIV, Hepatitis, Zika and Dengue Fever. HemaCare continues to expand its biorepository of cryopreserved peripheral blood mononuclear cells, popularly used for drug discovery and development projects. The disease state cells in greatest demand include various leukemias and lymphomas, multiple myeloma, solid tumors, and common autoimmune diseases. Researchers utilize immune cells or plasma and serum from patients with a diagnosed disease for pre-clinical research and testing for new therapies, including drug target discovery and effectiveness in the patient population. In addition to freshly collected blood products, HemaCare offers "matched sets" of cryopreserved PBMCs and plasma and/or serum from a variety of in-stock disease state samples.